Patents Assigned to Biogen, Inc.
-
Patent number: 5401642Abstract: Improved vectors and methods for expressing cloned genes of prokaryotic or eukaryotic origin and methods of making such vectors are disclosed, the improved vectors comprising promoters and operators from .lambda. phages and preferably do not include an active cro gene or an active N gene, the vectors having at least one endonuclease recognition site for cloning desired genes less than about 300 base pairs from the promoters and operators and being useful, as are methods utilizing the vectors, in producing a wide variety of prokaryotic, eukaryotic and vital polypeptides, hormones, enzymes, antigens, proteins and amino acids.Type: GrantFiled: May 7, 1993Date of Patent: March 28, 1995Assignee: Biogen, Inc.Inventors: Walter C. Fiers, Erik R. Remaut
-
Patent number: 5367056Abstract: DNA sequences encoding endothelial cell-leukocyte adhesion molecules ELAMs, methods for producing such molecules, and ELAMs (including the specific molecules ELAM1 and VLAM1 and 1b) essentially free of normally associated animal proteins are disclosed.DNA sequences encoding molecules involved in leukocyte adhesion (MILAs), methods for producing such molecules and MILAs (including the specific molecule, CDX) essentially free of normally associated animal proteins are also disclosed. Antibody preparations which are reactive for MILAs and also disclosed.Methods for identifying molecules which inhibit binding of leukocytes to endothelial cells, methods for inhibiting leukocyte binding to endothelial cells, and methods for detecting acute inflammation are disclosed.Type: GrantFiled: March 23, 1993Date of Patent: November 22, 1994Assignee: Biogen, Inc.Inventors: Catherine A. Hession, Roy R. Lobb, Susan E. Goelz, Laurelee Osborn, Christopher D. Benjamin, Margaret D. Rosa
-
Patent number: 5359033Abstract: This invention relates to cleaved dimers of Mullerian inhibiting substance-like polypeptides. More particularly, this invention relates to such dimers, methods of producing them and methods of using them in the treatment of cancer and tumors, especially those of the female genital tract. The dimers of this invention are also useful in compositions and methods for contraception.Type: GrantFiled: June 23, 1993Date of Patent: October 25, 1994Assignee: Biogen, Inc.Inventors: Richard L. Cate, R. Blake Pepinsky
-
Patent number: 5359032Abstract: This invention relates to interleukin inhibitors (IL-1 INHs) that selectively inhibit interleukin 1 activity. The invention also relates to processes for purifying such IL-1 INHs from urine and for producing such IL-1 INHs by hosts transformed with recombinant DNA molecules comprising DNA sequences encoding the inhibitors, and to methods of treatment and compositions characterized by such IL-1 INHs. These methods and agents are useful in immunosuppressive and anti-inflammatory applications and therapies.Type: GrantFiled: December 1, 1992Date of Patent: October 25, 1994Assignee: Biogen Inc.Inventors: Jean M. Dayer, Philippe L. Seckinger, Gonzalo J. Mazzei, Alan R. Shaw
-
Patent number: 5354665Abstract: A phosphatidylinositol (PI)-linked form of the LFA-3 polypeptide, which binds to CD2 molecules on the surface of T lymphocytes, in provided. Soluble polypeptides derived from the native sequence are also disclosed. DNA sequences, vectors, and transformed unicellular hosts useful for making these polypeptides are provided. Methods for using the LFA-3 polypeptides in therapy an diagnosis are described.Type: GrantFiled: October 13, 1992Date of Patent: October 11, 1994Assignee: Biogen, Inc.Inventors: Barbara P. Wallner, Catherine Hession
-
Patent number: 5298489Abstract: Human lipocortins III, IV, V and VI, DNA sequences and recombinant DNA molecules that are characterized in that they code for these human lipocortins. Hosts transformed with these sequences may be employed in the processes of this invention to produce the human lipocortin molecules of this invention. These polypeptides possess anti-inflammatory activity and are useful in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases.Type: GrantFiled: March 13, 1991Date of Patent: March 29, 1994Assignee: Biogen, Inc.Inventors: Barbara P. Wallner, R. Blake Pepinsky, Jeffrey L. Browning
-
Patent number: 5272263Abstract: DNA sequences encoding vascular cell adhesion molecules 1 and 1b ("VCAM1" and "VCAM1B"), recombinant DNA molecules comprising those sequences, and unicellular hosts transformed with those recombinant DNA molecules.Type: GrantFiled: December 18, 1989Date of Patent: December 21, 1993Assignee: Biogen, Inc.Inventors: Catherine A. Hession, Roy R. Lobb, Susan E. Goelz, Laurelee Osborn, Christopher D. Benjamin, Margaret D. Rosa
-
Patent number: 5272254Abstract: DNA sequences, hybrid DNA sequences, recombinant DNA molecules and processes for producing streptavidin-like polypeptides and for producing fused proteins consisting of a streptavidin-like polypeptide joined end to end with another protein, polypeptide, peptide or amino acid. The DNA sequences, hybrid DNA sequences and recombinant DNA molecules of this invention are characterized in that they include DNA fragments that code for streptavidin-like polypeptides. These DNA sequences, hybrid DNA sequences and recombinant DNA molecules and the hosts transformed with them may be employed in the processes of this invention to produce streptavidin-like polypeptides and fused proteins.Type: GrantFiled: November 27, 1991Date of Patent: December 21, 1993Assignee: Biogen Inc.Inventors: Harry M. Meade, Jeffrey L. Garwin
-
Patent number: 5256559Abstract: This invention relates to anticoagulant and platelet inhibitory compositions, combinations and methods characterized by biologically active peptides which display the anticoagulant and platelet inhibitory activities of hirudin, or analogs thereof, for therapeutic and prophylactic purposes. The methods, compositions and combinations of this invention are advantageously useful for decreasing or preventing platelet aggregation and platelet activation in a patient or a biological sample. These methods, compositions and combinations are particularly useful in patients for whom standard heparin therapy is contraindicated due to a history of heparin-induced thrombocytopenia or an antithrombin III deficiency. This invention also relates to methods, compositions and combinations for treating extracorporeal blood and for increasing platelet storage life.Type: GrantFiled: March 27, 1991Date of Patent: October 26, 1993Assignees: Biogen, Inc., Trustees of Boston UniversityInventors: John M. Maraganore, Joseph A. Jakubowski
-
Patent number: 5242810Abstract: The present invention relates to novel, bifunctional inhibitors of both platelet activation and thrombin. These bifunctional inhibitors are characterized by two domains -- a glycoprotein IIb/IIIa inhibitory domain and a thrombin inhibitory domain. The invention also relates to DNA sequences which encode the bifunctional inhibitors of this invention, recombinant DNA molecules which contain these DNA sequences and host transformed with these DNA molecules. The invention further relates to he recombinant expression of the bifunctional inhibitors of this invention by transformed hosts as well as to methods for purifying such recombinant bifunctional inhibitors. This invention also provides compositions and methods employing the novel bifunctional inhibitors alone or together with a fibrinolytic agent.Type: GrantFiled: December 7, 1990Date of Patent: September 7, 1993Assignee: Biogen, Inc.Inventors: John M. Maraganore, Betty H. Chao, Kathryn L. Strauch, Jeffrey S. Thompson
-
Patent number: 5242811Abstract: A process for selecting DNA sequences that are optimal for the production of polypeptides in hosts transformed with those DNA sequences. These DNA sequences, which code for a variety of human and animal proteins, permit the high level expression of those products in host cells. In the preferred embodiment of this invention, DNA sequences optimal for the production of human somatomedin C are selected and employed to express that growth enhancing factor.Type: GrantFiled: October 21, 1992Date of Patent: September 7, 1993Assignee: Biogen, Inc.Inventors: Gary N. Buell, Nageswararao Movva
-
Patent number: 5240913Abstract: This invention relates to novel biologically active molecules which bind to and inhibit thrombin. These molecules comprise a catalytic site directed moiety (CSDM) of the formula ##STR1## wherein X is hydrogen or is characterized by a backbone chain consisting of from 1 to 100 atoms; R.sub.1 is selected from the group consisting of unsubstituted, monosubstituted, di-substituted and tri-substituted saturated ring structures; R.sub.2 is a bond or is characterized by a backbone chain consisting of from 1 to 5 atoms; R.sub.3 is a bond or is characterized by a backbone chain consisting of from 1 to 3 atoms; R.sub.4 is any amino acid; R.sub.5 is any L-amino acid which comprises a guanidinium- or amino-containing side chain group; R.sub.6 is a non-amide bond; and Y is characterized by a backbone chain consisting of from 1 to 9 atoms; or the formula: ##STR2## wherein R'.sub.1 is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted ring structures; R'.sub.Type: GrantFiled: February 8, 1991Date of Patent: August 31, 1993Assignee: Biogen, Inc.Inventors: John M. Maraganore, Jo-Ann M. Jablonski, Paul R. Bourdon
-
Patent number: 5223394Abstract: DNA sequences derived from a phosphatidylinositol-linked form of lymphocyte function-associated antigen 3 ("LFA-3") are provided which code for a phosphatidylinositol linkage signalling sequence. The linkage signalling sequence may be linked to DNA coding for secretory proteins or polypeptides to obtain phosphatidylinositol-linked chimeric proteins or polypeptides. The chimeric proteins can be used to produce targeted drugs, to form micellular or liposomal drug delivery systems, or to improve the purification or screening of particular cells, proteins or DNA libraries.Type: GrantFiled: April 10, 1989Date of Patent: June 29, 1993Assignee: Biogen, Inc.Inventor: Barbara P. Wallner
-
Patent number: 5219990Abstract: This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. Native full-length E2 trans-activation protein activates transcription of papillomavirus only through binding to DNA, and it binds to DNA only in the form of a pre-formed homodimer--a pair of identical polypeptide subunits held together by non-covalent interactions. The E2 trans-activation repressors of this invention are proteins, polypeptides or other molecules that dimerize with full-length native E2 polypeptides to form inactive heterodimers, thus interfering with the formation of active homodimers comprising full-length native E2 polypeptides, thereby repressing papillomavirus transcription and replication. The E2 trans-activation repressors of this invention are advantageously used in the treatment of papillomavirus infections and their associated diseases.Type: GrantFiled: January 28, 1991Date of Patent: June 15, 1993Assignees: Biogen, Inc., New England Medical Center Hospitals, Inc.Inventors: Elliot J. Androphy, James G. Barsoum
-
Patent number: 5217870Abstract: Monoclonal antibodies against CDX, a leukocyte cell surface molecule that is a ligand of ELAM 1, and methods for producing them. Monoclonal antibody SGB.sub.3 B.sub.4 and monoclonal antibodies reactive to the same epitope. These monoclonal antibodies inhibit leukocyte-endothelial cell adhesion.Type: GrantFiled: April 28, 1989Date of Patent: June 8, 1993Assignee: Biogen, Inc.Inventors: Catherine A. Hession, Roy R. Lobb, Susan E. Goelz
-
Patent number: 5196403Abstract: The present invention relates to polypeptide inhibitors of platelet activation and derivatives thereof, purified from the venom of the North American Water Moccasin and to methods for their purification. This invention also relates to DNA sequences and recombinant DNA molecules which code for these polypeptide inhibitors of platelet activation. And this invention relates to recombinant DNA molecules which code for fusion proteins comprising both a polypeptide inhibitor of platelet activation and a conventional anti-thrombin polypeptide. This invention also relates to pharmaceutically acceptable compositions and methods characterized by at least one of these natural or recombinant inhibitors of platelet activation, alone or in combination with conventional anti-thrombin compounds. The compositions, combinations and methods of this invention are particularly useful in the treatment of thrombotic diseases.Type: GrantFiled: July 23, 1991Date of Patent: March 23, 1993Assignees: Biogen, Inc., Trustees of Boston UniversityInventors: John M. Maraganore, Joseph A. Jakubowski, Betty H. Chao
-
Patent number: 5196404Abstract: This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding exosite association moiety (ABEAM); a linker portion of at least 18 .ANG. in length; and a thrombin catalytic site-directed moiety (CSDM). This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.Type: GrantFiled: July 6, 1990Date of Patent: March 23, 1993Assignees: Biogen, Inc., Health Research, Inc.Inventors: John M. Maraganore, John W. Fenton, II, Toni Kline
-
Patent number: 5185441Abstract: Polypeptides that bind to CD2, the receptor on the surface of T-lymphocytes. Most preferably, the polypeptides are soluble. DNA sequences that code on expression and/or secretion in appropriate unicellular hosts for those polypeptides.Type: GrantFiled: August 26, 1988Date of Patent: February 9, 1993Assignee: Biogen, Inc.Inventors: Barbara P. Wallner, Catherine Hession
-
Patent number: 5182196Abstract: Recombinant DNA molecules comprising DNA sequences derived from bacteriophage T4 that are useful in expressing desired polypeptides in unexpectedly high yields, hosts and expression systems comprising such recombinant DNA molecules and methods for expressing desired polypeptides in high yields by the utilization of such hosts and expression systems.Type: GrantFiled: June 27, 1989Date of Patent: January 26, 1993Assignee: Biogen, Inc.Inventors: Bernard Allet, Eric H. Kawashima
-
Patent number: 5182260Abstract: The present invention relates to polypeptide inhibitors of platelet activation and derivatives thereof, purified from the venom of the North American Water Moccasin and to methods for their purification. This invention also relates to DNA sequences and recombinant DNA molecules which code for these polypeptide inhibitors of platelet activation. And this invention relates to recombinant DNA molecules which code for fusion proteins comprising both a polypeptide inhibitor of platelet activation and an anti-thrombin polypeptide. This invention also relates to pharmaceutically acceptable compositions and methods characterized by at least one of these natural or recombinant inhibitors of platelet activation, alone or in combination with anti-thrombin compounds. The compositions, combinations and methods of this invention are particularly useful in the treatment of thrombotic diseases.Type: GrantFiled: November 1, 1989Date of Patent: January 26, 1993Assignees: Biogen, Inc., Trustees of Boston UniversityInventors: John M. Maraganore, Joseph A. Jakubowski